On 12 June 2009, orphan designation (EU/3/09/645) was granted by the European Commission to Camurus AB, Sweden, for octreotide chloride (lipid depot solution) for the treatment of acromegaly.
The sponsorship was transferred to Novartis Europharm Limited, United Kingdom, in April 2014, then to Novartis Europharm Limited, Ireland, in May 2018 and finally back to Camurus AB, Sweden, in July 2018.
Octreotide chloride (lipid depot solution)
|Disease / condition||
Treatment of acromegaly
|Date of decision||
|Orphan decision number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.